C M Bidwell & Associates LTD Arcus Biosciences, Inc. Transaction History

C M Bidwell & Associates LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$15.96 - $23.15 $2,074 - $3,009	130 New	130 $2,000
Q2 2022 Aug 12, 2022	SELL	$17.23 - $37.73 $51,948 - $113,755	-3,015 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$31.38 - $48.47 $94,610 - $146,137	3,015 New	3,015 $122,000
Q2 2021 Aug 13, 2021	SELL	$22.75 - $35.77 $57,330 - $90,140	-2,520 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$26.16 - $41.39 $65,923 - $104,302	2,520 New	2,520 $71,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of C M Bidwell & Associates LTD, based on Form 13F filings with the SEC.

Stay updated on C M Bidwell & Associates LTD with notifications on news.